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Background: To assess the safety and efficacy of Stereotactic Ablative Radiotherapy (SABR) in oligometastatic
patients from colorectal cancer.
Methods: 82 patients with 1–3 inoperable metastases confined to one organ (liver or lung), were treated with
SABR for a total of 112 lesions in an observational study. Prescription dose ranged between 48 and 75Gy in 3 or 4
consecutive fractions. Primary end-points were local control (LC), overall survival (OS) and progression-free survival
(PFS). Secondary end-point was toxicity.
Results: Median follow-up was 24 months (range 3–47). One, two and three years LC rate was 90%,80% and 75%
(85%,75% and 70% for lung and 95%, 90% and 85% for liver metastases; no statistically significance was found). The
difference in LC between the subgroup of lesions treated with ≥60 Gy (n = 58) and those irradiated with <60 Gy
(n = 52) was statistically significant, with a 1, 2 and 3 yrs LC of 97%,92% and 83% for the higher dose, compared to
85%,70% and 70% for the lower dose (p < 0.04). Median OS was 32 months. Actuarial OS rate at 1, 2 and 3 yrs was
85%,65% and 43%. Univariate analysis showed a correlation only between OS and cumulative GTV > 3 cm (p < 0.02).
Median PFS was 14 months, with a PFS rate of 56% at 1 yr and 40% at 2-3 yrs, without correlation with the site and
prescription dose (p < 0.48 and p < 0.56). No patients experienced radiation-induced liver disease or grade >3 toxicity.
Conclusions: SABR is a safe and feasible alternative treatment of oligometastatic colorectal liver and lung metastases
in patients not amenable to surgery or other ablative treatments.
Keywords: Liver, Lung, Colorectal oligometastases, RapidArc, Stereotactic ablative radiotherapyBackground
The concept of “oligometastatic disease” was introduced
to identify a condition in which the number and sites of
metastases are limited from one to five [1]. According to
this hypothesis of orderly progression, this is an inter-
mediate state before widespread dissemination. Therefore,
the local control of oligometastases could still improve the
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unless otherwise stated.Conversely, studies suggested that oligometastases can
represent only the clinically detectable lesions in the
context of widespread occult disease and their treat-
ment may not affect survival [2]. Presumably, both hy-
pothesis are correct [3]. Given the improvements in
diagnostic imaging, the prevalence of oligometastatic
state is increasing [4].
Colorectal cancer (CRC) is one of the tumors that most
often presents solitary recurrence or oligometastasis, com-
monly in the liver and lung [5]. The surgical resection is
associated with a survival increase [6-11]. The hepatic
resection can provide a 5-year overall survival (OS) rates
of 37–58% [6,7], as well as the pulmonary resection canLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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proximately 70-90% of metastatic patients, however, are
unresectable because of technical difficulties, unfavor-
able tumor factors or patients co-morbidities [7,8,10].
Other local approaches, such as radiofrequency ablation
(RFA), have been used as alternative to surgical resection
of CRC metastasis. Also these techniques presents some
limitations related to the size and location of the target
lesions [12-14].
The use of Stereotactive Ablative Body Radiation Ther-
apy (SABR) was investigated in the treatment of oligome-
tastasis with promising results, utilizing either a single
dose or a small number of fractions [15]. The SABR ap-
proach has proved an effective treatment for inoperable
liver and lung metastases [16-19], particularly in terms of
local control (LC).
This prospective study examined patients with liver
and lung oligometastases by colorectal cancer not amen-
able to surgery or other local treatments, treated with
SABR by means of volumetric modulated arc therapy (in
RapidArc, RA, form).
We hypothesized that for the setting of CRC patients,
who are in this intermediate, potentially-curative oligo-
metastatic state, the ablative radiation treatment of inop-
erable recurrences can represent an efficacy therapeutic
option.
Methods
Patients selection
82 patients with 1–3 detectable metastasis from CRC,
confined to one organ (liver or lung) were prospectively
enrolled and treated with SABR between February 2010
and January 2013 according to the methods described in
[18] in an observational, non-interventional study (per-
formed with the approval of the Humanitas Cancer Center
Ethical Review Committee and in compliance with the
Helsinki Declaration) to assess the safety and effectiveness
of SABR. SABR was prescribed by the radiation oncologist
as part of standard care for these patients if presented:
histologically proven colorectal adenocarcinoma, radical
resection of the primary tumor, 1–3 lesions confined to
one organ such as the liver or lung, assessed as inoper-
able (due to technical reasons or to concomitant co-
morbidities as cardiac diseases) and not amenable to an-
other local treatment, with a maximum tumor diameter
less than 6 cm, no evidence of progressive or untreatedTable 1 Summary of the risk-adapted dose prescription accor
Dose
Distance to
Lung oligometastases (n = 60) 60 Gy/3 fr (n = 6) >1
48 Gy/4 fr (n = 54) >1
Liver oligometastases (n = 52) 75 Gy/3 fr (n = 52)gross disease outside the liver and lung, no prior radiation
therapy to the targeted area, no concurrent chemotherapy,
either within 14 days before SABR or until the first revalu-
ation, normal liver volume greater than 1000 cm3; adequate
hepatic and pulmonary function, no active connective tis-
sue disorders; Karnofsky Performance Status of 70; mini-
mum age of 18; and ability to provide a written informed
consent.
SABR technique
The SABR technique used has been reported in detail in
[18,20]. The patients were immobilized with a thermoplas-
tic body mask, including (for liver) a Styrofoam block for
abdominal compression. A contrast-free computed tomog-
raphy (CT) scan were acquired for all patient and the 3
phases contrast-enhanced CT were acquired for patient
with hepatic metastases. The 4-dimensional CT (4D-CT)
imaging was performed in all patients with lung metastases
and in 11 patients (30.5%) with hepatic metastases because
a respiratory excursion was greater of 5 mm. In most of
the patients, planning CT images were co-registered with
magnetic resonance imaging (MRI) or positron emission
tomography (PET) to better identify the gross tumor vol-
ume (GTV). The clinical target volume (CTV) was defined
as equal to the GTV. In all patients who underwent
4D-CT scan, an internal target volume (ITV) was defined
as the envelope of all GTVs in the different respiratory
phases. The planning target volume (PTV) was generated
from either the GTV or the ITV by adding an isotropic
margin of 5 mm from ITV or of 7-10 mm in the cranial-
caudal axis and 4-6 mm in the anterior-posterior and lat-
eral axes from CTV.
The risk-adapted dose prescription was according to
lesion site and OARs constraints respect, as showed in
Table 1. For liver metastases the prescription derives
from the results of the phase II trial performed at the in-
stitute [18] while for the lung metastases the risk adaptive
prescription scheme is derived from institutional policies
inspired to the National Comprehensive Cancer Network
guidelines for lung cancer. The plan objective was to cover
at least 98% of the CTV (ITV) volume with 98% of the
prescribed dose (V98% = 98%) and for the PTV to cover
95% of the volume with 95% of the dose (V95% = 95%).
Planning constraints for the organs at risk were derived
from the earlier studies and included for the liver me-
tastases: V15Gy (volume receiving 15 Gy ) < (total liverding to lesion site and OARs constraints respect
Topografical Criteria
chest wall Size Distance to main bronchus
cm <2 cm >2 cm
cm <2 cm and <5 cm >2 cm
<6 cm
Table 2 Patients characteristics
Patients number 82
Mean age (range) y 68 (40–87)
Sex (M:F) 62:21
Primary
Colon 58 (71%)
Rectum 24 (29%)
TNM Primary Classification
T1 2 (3%)
T2 17 (21)
T3 57 (70%)
T4 6(7%)
N0 39 (48%)
N1-2 43 (52%)
M1 23 (28%)
Only liver 42 (51%)
Only lung 40 (49%)
Timing of liver metastases
Synchronous 23 (28%)
Metachronous 59 (82%)
DFI≤ 12 months 14 (24%)
DFI > 12 months 45 (76%)
Previous local treatments
Surgery 33 (40%)
RFA or other 7 (9%)
Systemic treatments
Pre-SBRT chemotherapy 78 (95%)
Post-SBRT chemotherapy 20 (24%)
Time of SBRT since diagnosis
<12 mo 7 (8%)
>12 mo 75 (92%)
No. of prior systemic
treatment regimens
0 4 (5%)
1 15 (18%)
2 25 (30%)
3 23 (28%)
>4 15 (19%)
Presence of stable extrahepatic
and pulmonary metastatic
disease at diagnosis
Yes 27 (33%)
No 55 (67%)
Number of lesions treated 112
Table 2 Patients characteristics (Continued)
Number of lesions for patients Tot Liver Lung
1 61 (74%) 35 (83%) 26 (65%)
2 13 (16%) 4 (10%) 9 (23%)
3 8 (10%) 3 ( 7%) 5 (12%)
Mean volume (range) [cm3]
CTV 20.3 ± 24.09 (1.0-140.3)
PTV 60.60 ± 42.16 (6.3-980.13)
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ing PTV, constraints of V5Gy < 30%, V10Gy < 20%, V20Gy < 10
were set and a mean dose <4Gy was accepted. Treatment
was delivered on a Varian TrueBeam linear accelerator
using a 10 MV Flattening Filter Free beam with a max-
imum nominal dose rate of 2400 MU/minute with the
RapidArc technique.Response assessment
Tumor response was defined using European Organization
for Research and Treatment of Cancer Response Evaluation
Criteria In Solid Tumors (EORTC-RECIST) 1.1 [21].
Time to local progression was calculated as the time
from the first day of SABR to day of first progressive
disease of the irradiated lesions. Patients were ob-
served for local control, even if distant or new liver or
lung metastases developed. PFS included any intra- or
extra-hepatic and pulmonary disease progression.
After conclusion of SABR, these examinations were re-
quested 21 days after and then every 2 months. Imaging
for follow-up included CT scans every 3 months and,
with the same periodicity, PET-CT was also available for
a subgroup of 54% of patients. Acute and late toxicity
were scored by the Common Terminology Criteria for
Adverse Events 3.0. Any increase in grade from baseline
was considered toxicity related to the treatment. RILD
was defined by Lawrence’s criteria.
Kaplan–Meier method was used to generate the actuar-
ial LC, OS and PFS curves. Log rank test was used for
group comparison. All calculations were performed using
SPSS version 13.0 (SPSS Inc., Chicago, Illinois). Univariate
analysis was used to correlate morphologic and clinical
factors to LC , OS and PFS and statistical significance was
accepted for p-values of < 0.05.Results
Patients and treatments characteristics
Eighty-two patients for a total of 112 single-site metasta-
ses were analyzed. Mean age was 68 years (range, 40–
87years). Median follow-up was 24 months with range
from 3 to 47 months. Five patients had a short follow-up
(less than 6 months) because of early death. The summary
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Table 2. Forty- two patients were treated for a total of 52
liver lesions; 41 patients were irradiated for a total of 60
lung lesions.
In most of patients (92%) the PFS calculated from diag-
nosis of metastatic disease to SABR time was >12 months.
Number of treated lesions was 1 in 61 (74%) patients, 2 in
13 (16%) patients and 3 in 8 (10%) patients. Mean lesion
size was 3.3 cm (range 1.1 – 5.0 cm). Prescription dose
ranged between 48 and 75 Gy in 3 or 4 consecutive frac-
tions and was performed according to metastases site and
organs at risk (OARs) constraints (Table 2). For 58 lesions
the prescription dose was ≥ 60 Gy (6 lung metastasis and
all 52 liver metastases), for the remaining 54 lung lesions
the prescription dose was <60 Gy.
Local control, progression free survival and overall
survival
Figure 1 shows a complete response at 3 months FU
with PET imaging in two patients with liver and lung
metastases. One, two and three years LC rate was 90%,
80% and 75%, respectively (Figure 2a). Complete response
was achieved in 44 (39%) lesions, partial response in 28
(25%), stable disease in 22 (20%) and progression disease
in 18 (16%). The patterns of local response according to
site of metastases is showed in Table 3.
Five patients for a total of 5 lesions (4%) developed in-
field liver recurrence at 5, 10, 13, 14 and 29 months, with
a median time to liver local progression of 17 months. No48Gy/
75Gy/3
Before RT
Before RT
Figure 1 Examples of complete response in two patients with liver ancorrelation was observed between LC and PTV or CTV
coverage (also in the cases with relatively low minimum
dose to PTV). The minimum dose for the 5 recurrent pa-
tients ranged from 65.2 to 68.3 Gy (87 to 91% of the pre-
scription). Six patients for a total of 13 lesions developed
lung recurrence: 1 lesion at 6 months, 2 at 8 months, 5 at
10 months, 1 at 13 months, 3 at 18 months and 1 at
23 months, with a median time to lung local progression
of 7 months. Also for these cases no correlation between
LC and CTV or PTV coverage was detected.
At subgroup analysis, the LC at 1,2 and 3 years, was
85%, 75% and 70% for lung metastases and 95%, 90%
and 85% for liver metastases, respectively, even though
difference was not statistically significant (p < 0.09). The
difference in LC between the subgroup of lesions treated
with dose ≥60 Gy (n = 58) and those irradiated with dose
<60 Gy (n = 54) was statistically significant, with a 1,2
and 3 years LC of 97%,92% and 83%, respectively, for the
higher ablative dose, compared to 85%, 70% and 70%, re-
spectively, for the lower dose (p < 0.04), as showed in
Figure 2b. No correlation with cumulative GTV dimen-
sions, number of lesions or other factors was detected.
Forty-five (55%) patients presented with a progression
disease. Patterns of progression are shown in Table 3.
Median progression-free survival (PFS) was 14 months,
with a PFS rate of 56% at 1 year and 40% at 3 years
(Figure 2c), without correlation with the site and prescrip-
tion dose of irradiated metastases (p < 0.48 and p < 0.56,
respectively).4fr
fr
3 months FU
3 months FU
d lung metastases.
ab
c
d
e
Figure 2 Local control (a and b), Progression free survival (c) and Overall survival (d,e) curves.
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Table 3 Patterns of local response
Pattern of local response Liver metastases
(n = 52)
Lung metastases
(n = 60)
In-field response
Complete response (CR) 22 (43%) 22 (37%)
Partial response (PR) 17 (32%) 11 (18%)
Stable disease (SD) 8 (15%) 14 (23%)
Progressive disease (PD) 5 (10%) 13 (22%)
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lysis. Twenty-four (29%) died for cancer specific-causes,
whereas 6 (7%) died of other causes. Median OS was
32 months. Actuarial OS rate at 1,2 and 3 years was
85%,65% and 43%, respectively (Figure 2d). Univariate
analysis showed a correlation between OS and cumula-
tive GTV > 3 cm (p < 0.024), as showed in Figure 2e, but
not with the other analyzed prognostic factors ( i.e. pre-
scription dose, number and site of lesions, synchronous
or metachronous metastases, disease free interval, in case
of metachronous disease, greater or lesser than 12 months,
presence of extra-hepatic and extra-pulmonary metastatic
disease at the time of diagnosis, previous chemotherapy
regimens), as shown in Table 4. Disease specific survival
did not significantly differ from OS because most of the
patients died for cancer related causes (only 4 patients
died for other causes).
Toxicity
Fifty-four patients (70%) developed G2 acute toxicity.
The most frequent side effects were fatigue (60%) and
transient hepatic transaminase increase (25%), for liver
metastases treatment. No toxicity of grade 3 or greater
was observed. No patients developed RILD, chest pain
or rib fracture.
Discussion
Although the role of oligometastases ablation was often
controversial, evidence was provided to support theTable 4 Prognostic factors affecting LC and OS rates on univa
Factors Lesion (n°) LC (rates)
1 years 2 years 3 yea
Site of irradiated metastases
Lung 60 85% 75% 70%
Liver 52 95% 90% 81%
Cumulative GTV
< 3 cm - - - -
> 3 cm
SBRT dose
≥ 60 Gy 58 97% 92% 83%
< 60 Gy 52 85% 70% 70%efficacy of metastatic resection [5-11,22]. Liver and lung
are a common sites of progression in CRC, with an inci-
dence of 30-70% [5]. The modern chemotherapy regi-
mens have improved the prognosis of this
oligometastastic patients, but the surgery has allowed
the major results in terms of long-term outcomes [23].
Surgical resection improves OS, with 1- and 5-year rate
of 90-95% and 30-60%, respectively for liver metastases
and with 1- and 5-year OS rate of 85-90% and 38-50%
respectively, for lung metastases [6-11,22]. An increased
long-term cancer-specific survival at 10 years after resec-
tion was recently demonstrated [22]. About 80-90% of
metastatic patients, however, are not suitable for resec-
tion because of technical difficulties, unfavorable tumor
factors or patients co-morbidities [23,24]. RFA is a valid
alternative to surgery, with a LC rate of 90-98% at 1 year,
OS rates at 1–2 and 5-year of 87%-70% and 34%, re-
spectively, and median OS of 25 months [12-14]. Effi-
cacy of local therapies is acceptable in presence of small
lesions with diameter <3 cm and distant from vascular
or biliary structures. An effective and safe alternative
therapeutic option is necessary in about 60-80% of
CRC oligometastatic patients, which can benefit from
locally ablative therapy, as they are probably never fit
to surgery.
SABR represents such an alternative for tumor abla-
tion. Different from conventional radiotherapy, SABR
entails precise delivery of high-dose in few fractions,
with a complete tumor ablation and maximal normal-
tissue sparing. Prospective studies have supported the
use of SABR in oligometastatic patients [15]. The ration-
ale of oligometastatic ablation with SABR consists of a
very complex net of factors [25], to which the impact of
immune-modulation is added [26].
Many authors have shown the efficacy of SABR as a
local treatment of oligometastases in liver, lung and
lymph nodes from different primary cancers [16-19].
However, only few study are focused on the SABR for
inoperable oligometastases from CRC, with a limitedriate analysis
p value Patients (n°) OS (rates) p value
rs 1 years 2 years 3 years
0.095 40 87% 68% 58% 0.34
42 78% 61% 44%
- 47 90% 70% 61% 0.02
35 73% 56% 26%
0.043 46 80% 57% 38% 0.69
36 86% 54% -
Table 5 Published study on SBRT for oligometastases from CRC
Author, design study,
(reference)
Patients (n) Lesions (n) Dose
(Gy/ fr)
FUP (m) LC (%) OS (%) Median
PFS (m)
Acute
Toxicity
≥G3
1-year 2-yeras 1-year 2-years
Hoyer, Phase II (27) 44 - 45 Gy/3 fr 4.3 y 90% 79% 67% 38% 6.5 48%
Van der Pool,
Phase I-II (28)
20 31 37.5 Gy/3 fr 26 m 100% 74% 100% 83% 11 10%
45 Gy/3 fr
(2 pts)
Kang, Retrospective (29) 59 78 36–51 Gy/3 fr 32 m 85% 66% 82% 66% - 3%
14 Gy/1 fr
Bae Retrospective (30) 41 50 45–60 gy/3 fr 28 m 100% 85% 85% 70% - 7%
Current Study 82 112 48 Gy/4 fr 24m 85% 70% 85% 65% 14m 0%
60–75 Gy/3 fr 97% 92%
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(ranged between 31–78) treated, as shown in Table 5
[27-30].
In the present prospective analysis, 82 consecutive pa-
tients with a total of 112 single-site oligometastases from
CRC were treated with an ablative radiation dose ranged
between 45–75 Gy in 3 or 4 fractions.
All patients presented a single site of metastatic disease,
liver or lung , and a maximum of three lesions treated.
Median follow up was 24 months, 1,2 and 3-year LC rates
were 90%, 80% and 75%, respectively. Univariate analysis
showed a statistically significant improvement of LC in
the subgroup of lesions treated with a prescription
dose ≥ 60Gy. This is in agreement with several studies
focused on SBRT for liver metastases. Lee et al. [17]
confirmed the correlation between local control and
higher prescription dose, specially for lesion larger than
3 cm, as showed by Rusthoven et al. [16]. A pooled ana-
lysis on SBRT for CRC liver metastases by Chang et al.
[31] confirmed the better local control for lesion treated
with higher prescription dose and suggested the use of a
total dose > 48 Gy for a 3 fractions regimen of SBRT.
Improvement in LC is more evident after 1 year of
FU and confirms the importance of the use of ablative
doses in this subset of long- survival CRC oligometa-
static patients.
In our study, LC is not correlated to the cumulative
GTV (larger or smaller than 3 cm in diameter) when a
higher prescription dose is administered, according to
our results on SBRT for liver metastases [18]. This sug-
gests the utility of escalations dose of radiation in the
absence of severe complications. The improvement in
LC is more evident, in this study, after 1 year of FU
and confirms the importance of the use of ablative
doses in this subset of long-surviving CRC oligometa-
static patients.
Median OS was 32 months. Although the FU is still
short for a data comparison with the surgery and RFA,
these results are considered promising. This remark isstrengthened by univariate analysis, which showed a correl-
ation between OS and cumulative GTV > 3 cm (p < 0.02)
and a median OS of 44 months for a subgroup of patients
with lower cumulative GTV. OS was not influenced by
other prognostic factors (synchronous or metachronous
presentation, DFI, extra-hepatic or extra-pulmonary dis-
ease, previous chemotherapy regimens), according to data
published on SBRT. These data seems to be related to the
careful selection of these oligometastatic patients, most of
which (90%) presented a time-interval from diagnosis to
SABR > 12 months and a stable oligometastatic disease.
Correlation between OS and cumulative GTV, suggested
that it is important to perform SBRT in oligometastatic
patients before a wider spreading of disease.
Although median follow up of this study was 24 months,
results seem to encourage the use of SABR in the treat-
ment of CRC oligometastatic patients not eligible for sur-
gery and/or RFA because of tumor size and/or location
and patient comorbidities. This study has shown that
SABR, with a low toxicity profile, is a safe and effective
therapeutic option also for “frail” and elderly patients.
Conclusions
SABR is a safe, non-invasive and effective therapeutic
option for unresectable colorectal oligometastases and al-
lows to achieve promising rates of LC and OS. Dose higher
60 Gy are recommended to improve LC.
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